Due to high expression of the immune checkpoint molecule programmed death-1 (PD-1) and its ligand (PD-L1), immunotherapy, a type of treatment regulating T-lymphocyte activity and enhancing the antitumor immune response, may effectively reduce tumor immune escape and become a promising adjuvant therapy for advanced ICC (23–25). This evidence concerns the gene CD274 and neoplasm.